Trials / Completed
CompletedNCT00293046
Assessment of Grazax® Treatment Compliance
A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALK Grass tablet - use of compliance device |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-09-01
- Completion
- 2007-10-01
- First posted
- 2006-02-17
- Last updated
- 2008-09-30
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00293046. Inclusion in this directory is not an endorsement.